KoBioLabs (A348150) Stock Overview
Provides microbiome therapeutics for metabolic, immune, and neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A348150 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
KoBioLabs, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,000.00 |
| 52 Week High | ₩7,730.00 |
| 52 Week Low | ₩3,730.00 |
| Beta | 0.65 |
| 1 Month Change | -4.03% |
| 3 Month Change | 3.95% |
| 1 Year Change | -11.82% |
| 3 Year Change | -54.34% |
| 5 Year Change | -88.33% |
| Change since IPO | -84.03% |
Recent News & Updates
Is KoBioLabs (KOSDAQ:348150) Weighed On By Its Debt Load?
Nov 14
Market Might Still Lack Some Conviction On KoBioLabs, Inc (KOSDAQ:348150) Even After 36% Share Price Boost
Sep 02KoBioLabs, Inc (KOSDAQ:348150) Screens Well But There Might Be A Catch
Jul 14Take Care Before Diving Into The Deep End On KoBioLabs, Inc (KOSDAQ:348150)
Apr 09Recent updates
Is KoBioLabs (KOSDAQ:348150) Weighed On By Its Debt Load?
Nov 14Market Might Still Lack Some Conviction On KoBioLabs, Inc (KOSDAQ:348150) Even After 36% Share Price Boost
Sep 02KoBioLabs, Inc (KOSDAQ:348150) Screens Well But There Might Be A Catch
Jul 14Take Care Before Diving Into The Deep End On KoBioLabs, Inc (KOSDAQ:348150)
Apr 09Take Care Before Diving Into The Deep End On KoBioLabs, Inc (KOSDAQ:348150)
Nov 13Does KoBioLabs (KOSDAQ:348150) Have A Healthy Balance Sheet?
Sep 06Cautious Investors Not Rewarding KoBioLabs, Inc's (KOSDAQ:348150) Performance Completely
Jul 12We're Not Worried About KoBioLabsInc's (KOSDAQ:348150) Cash Burn
Apr 15What Type Of Shareholders Own The Most Number of KoBioLabs,Inc (KOSDAQ:348150) Shares?
Feb 18Shareholder Returns
| A348150 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.0% | 11.3% | 0.6% |
| 1Y | -11.8% | 46.7% | 61.5% |
Return vs Industry: A348150 underperformed the KR Biotechs industry which returned 46.7% over the past year.
Return vs Market: A348150 underperformed the KR Market which returned 61.5% over the past year.
Price Volatility
| A348150 volatility | |
|---|---|
| A348150 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 10.8% |
| 10% least volatile stocks in KR Market | 2.5% |
Stable Share Price: A348150's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A348150's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | GwangPyo Ko | kobiolabs.com |
KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and neurological diseases. The company is based in Seongnam-si, South Korea.
KoBioLabs, Inc Fundamentals Summary
| A348150 fundamental statistics | |
|---|---|
| Market cap | ₩100.20b |
| Earnings (TTM) | -₩8.28b |
| Revenue (TTM) | ₩69.48b |
Is A348150 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A348150 income statement (TTM) | |
|---|---|
| Revenue | ₩69.48b |
| Cost of Revenue | ₩18.46b |
| Gross Profit | ₩51.02b |
| Other Expenses | ₩59.30b |
| Earnings | -₩8.28b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -426.43 |
| Gross Margin | 73.43% |
| Net Profit Margin | -11.92% |
| Debt/Equity Ratio | 26.4% |
How did A348150 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 16:13 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KoBioLabs, Inc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.